Refine
Language
- English (4)
Has Fulltext
- yes (4)
Is part of the Bibliography
- no (4)
Keywords
- Asia (1)
- KCGS (1)
- Oceania (1)
- Prithinae (1)
- chemogenomic set (1)
- drug discovery (1)
- druggable genome (1)
- kinase inhibitor (1)
- new species (1)
- phenotypic screening (1)
The Kinase Chemogenomic Set (KCGS): an open science resource for kinase vulnerability identification
(2021)
We describe the assembly and annotation of a chemogenomic set of protein kinase inhibitors as an open science resource for studying kinase biology. The set only includes inhibitors that show potent kinase inhibition and a narrow spectrum of activity when screened across a large panel of kinase biochemical assays. Currently, the set contains 187 inhibitors that cover 215 human kinases. The kinase chemogenomic set (KCGS), current Version 1.0, is the most highly annotated set of selective kinase inhibitors available to researchers for use in cell-based screens.
The Kinase Chemogenomic Set (KCGS): An open science resource for kinase vulnerability identification
(2019)
We describe the assembly and annotation of a chemogenomic set of protein kinase inhibitors as an open science resource for studying kinase biology. The set only includes inhibitors that show potent kinase inhibition and a narrow spectrum of activity when screened across a large panel of kinase biochemical assays. Currently, the set contains 187 inhibitors that cover 215 human kinases. The kinase chemogenomic set (KCGS) is the most highly annotated set of selective kinase inhibitors available to researchers for use in cell-based screens.
Labahitha spiders (Arachnida: Araneae: Filistatidae) from islands in the Indian and Pacific Ocean
(2022)
The genus Labahitha has hitherto comprised two species from peninsular Malaysia and Christmas Island (Australia). We here demonstrate that the genus is widespread in islands and territories across the Indian and Pacific Oceans, including the following species that have been previously assigned to other filistatid genera: Labahitha marginata (Kishida, 1936) comb. nov. (= Filistata bakeri Berland, 1938 syn. nov.), Labahitha garciai (Simon, 1892) comb. nov. (= Pritha heikkii Saaristo, 1978 syn. nov., = Pritha sechellana Benoit, 1978 syn. nov.), Labahitha nicobarensis (Tikader, 1977) comb. nov., Labahitha littoralis (Roewer, 1938) comb. nov., Labahitha insularis (Thorell, 1891) comb. nov., Labahitha sundaica (Kulczyński, 1908) comb. nov. (all transferred from Pritha, the latter three provisionally, pending re-examination of the type material); Labahitha fuscata (Nakatsudi, 1943) comb. nov. and Labahitha ryukyuensis (Ono, 2013) comb. nov. (both transferred from Tricalamus). Many of these species have been collected in synanthropic settings and from disparate islands thousands of kilometers apart. This suggests either high dispersal capabilities or, more likely, human-mediated introductions. At least L. marginata has been introduced to continental America. Two new species of Labahitha are described: Labahitha platnicki sp. nov. from New Caledonia and the Bismarck Islands and Labahitha incerta sp. nov. from Queensland, Australia. The male of Labahitha gibsonhilli (Savory, 1943) is reported for the first time. Wandella loloata sp. nov. is described from Papua New Guinea, representing the first record of this genus outside Australia. Pritha hasselti (Simon, 1906) from Indonesia is shown to be a Filistatinae, and thus the species is provisionally transferred back to Filistata.
Protein kinases are highly tractable targets for drug discovery. However, the biological function and therapeutic potential of the majority of the 500+ human protein kinases remains unknown. We have developed physical and virtual collections of small molecule inhibitors, which we call chemogenomic sets, that are designed to inhibit the catalytic function of almost half the human protein kinases. In this manuscript we share our progress towards generation of a comprehensive kinase chemogenomic set (KCGS), release kinome profiling data of a large inhibitor set (Published Kinase Inhibitor Set 2 (PKIS2)), and outline a process through which the community can openly collaborate to create a KCGS that probes the full complement of human protein kinases.